Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


5% ww Diclo K drops


Thanks to the Patented Dynamic Buffering Technology (DBT) , oral drops 50 mg/ml has the following advantages compared with competing products:

> Unique , not replaceable NSAID formulation for Migraine, effective as Triptans

> Very Short Onset of Action (15min)

> Reduced Side Effects compared to Triptans

> Cost competitive

> Large Market: Indicated for Migraine, Acute Pain and Post-operative pain




Complete
Non confidential
Opportunity
Profile









Search results